NovoCure Limited NVCR

Company Overview

NovoCure Limited is a commercial-stage oncology company focused on the development and commercialization of Tumor Treating Fields (TTFields), a proprietary, non-invasive cancer therapy that uses alternating electric fields to disrupt cancer cell division. The company operates within the medical devices and oncology therapeutics industries, with its core offering designed to treat solid tumors. NovoCure’s primary revenue driver is the sale and rental of its TTFields systems, marketed under the Optune brand, which are prescribed for use alongside standard-of-care cancer treatments.

The company’s lead products include Optune for glioblastoma and Optune Lua for malignant pleural mesothelioma, both of which have received regulatory approvals in major markets. NovoCure’s unique positioning lies in its focus on a novel biophysical mechanism of action that is distinct from pharmaceuticals and biologics, supported by randomized clinical trial data. Founded in 2000, the company evolved from an early-stage research organization into a publicly listed commercial enterprise, completing its initial public offering in 2015 and expanding its clinical pipeline and global footprint thereafter.